Sagimet Biosciences Inc.
SGMTNASDAQHealthcare● Active
$6.70
+$0.17(+2.58%)
Market Cap$218252425
P/E Ratio—
52W High$11.41
52W Low$4.5
Sagimet Biosciences Inc. (SGMT) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
SGMT · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 12, 2026EPS Actual
-$0.33
Est. -$0.39 · +15.4%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 12, 2026
After Market Close
▲ Beat EPS🔥 9-Quarter EPS Beat Streak
SGMT reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $6.21B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$6.21B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 12, 2026 | -$0.26 | — | — | — | — | — |
| ▲ Q2 FY2026 | May 12, 2026 | -$0.39 | -$0.33 | +15.4% | — | — | — |
| ▲ Q1 FY2026 | Mar 11, 2026 | -$0.43 | -$0.29 | +32.6% | — | $0.00B | — |
| ▲ Q4 FY2025 | Nov 13, 2025 | -$0.41 | -$0.40 | +2.4% | — | — | — |
| ▲ Q3 FY2025 | Aug 13, 2025 | -$0.52 | -$0.32 | +38.5% | — | — | — |
| ▲ Q2 FY2025 | May 8, 2025 | -$0.79 | -$0.56 | +29.1% | — | — | — |
| ▲ Q1 FY2025 | Mar 12, 2025 | -$0.65 | -$0.50 | +23.1% | — | — | — |
| ▲ Q4 FY2024 | Nov 14, 2024 | -$0.47 | -$0.45 | +4.3% | — | — | — |
Q3 FY2026
Aug 12, 2026
EPS Actual
—
EPS Est.
-$0.26
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 12, 2026Beat
EPS Actual
-$0.33
EPS Est.
-$0.39
EPS Surpr.
+15.4%
Revenue
—
Q1 FY2026
Mar 11, 2026Beat
EPS Actual
-$0.29
EPS Est.
-$0.43
EPS Surpr.
+32.6%
Revenue
—
Q4 FY2025
Nov 13, 2025Beat
EPS Actual
-$0.40
EPS Est.
-$0.41
EPS Surpr.
+2.4%
Revenue
—
Q3 FY2025
Aug 13, 2025Beat
EPS Actual
-$0.32
EPS Est.
-$0.52
EPS Surpr.
+38.5%
Revenue
—
Q2 FY2025
May 8, 2025Beat
EPS Actual
-$0.56
EPS Est.
-$0.79
EPS Surpr.
+29.1%
Revenue
—
Q1 FY2025
Mar 12, 2025Beat
EPS Actual
-$0.50
EPS Est.
-$0.65
EPS Surpr.
+23.1%
Revenue
—
Q4 FY2024
Nov 14, 2024Beat
EPS Actual
-$0.45
EPS Est.
-$0.47
EPS Surpr.
+4.3%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.20 | $-0.20 | $-0.20 | 2 |
| Q3 FY2027 | $-0.26 | $-0.26 | $-0.26 | 2 |
| Q2 FY2027 | $-0.23 | $-0.23 | $-0.23 | 2 |
| Q1 FY2027 | $-0.21 | $-0.21 | $-0.21 | 2 |
| Q4 FY2026 | $-0.32 | $-0.32 | $-0.32 | 4 |
| Q3 FY2026 | $-0.29 | $-0.25 | $-0.20 | 6 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 7 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 4 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 6 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 4 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 7 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 4 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 12, 2026 | +15.4% | $7.69 | $7.65 | -0.52% |
| ▲ Q1 FY2026 | Mar 11, 2026 | +32.6% | $5.53 | $5.74 | +3.80% |
| ▲ Q4 FY2025 | Nov 13, 2025 | +2.4% | $8.82 | $7.74 | -12.24% |
| ▲ Q3 FY2025 | Aug 13, 2025 | +38.5% | $9.55 | $9.58 | +0.31% |
| ▲ Q2 FY2025 | May 8, 2025 | +29.1% | $3.34 | $3.20 | -4.19% |
| ▲ Q1 FY2025 | Mar 12, 2025 | +23.1% | $3.40 | $3.51 | +3.24% |
| ▲ Q4 FY2024 | Nov 14, 2024 | +4.3% | $6.02 | $5.18 | -13.95% |
| ▲ Q3 FY2024 | Aug 14, 2024 | +26.5% | $2.66 | $2.47 | -7.14% |
Q2 FY2026-0.52%
Report Date
May 12, 2026
EPS Beat/Miss
+15.4%
Price Before
$7.69
Price After
$7.65
Q1 FY2026+3.80%
Report Date
Mar 11, 2026
EPS Beat/Miss
+32.6%
Price Before
$5.53
Price After
$5.74
Q4 FY2025-12.24%
Report Date
Nov 13, 2025
EPS Beat/Miss
+2.4%
Price Before
$8.82
Price After
$7.74
Q3 FY2025+0.31%
Report Date
Aug 13, 2025
EPS Beat/Miss
+38.5%
Price Before
$9.55
Price After
$9.58
Q2 FY2025-4.19%
Report Date
May 8, 2025
EPS Beat/Miss
+29.1%
Price Before
$3.34
Price After
$3.20
Q1 FY2025+3.24%
Report Date
Mar 12, 2025
EPS Beat/Miss
+23.1%
Price Before
$3.40
Price After
$3.51
Q4 FY2024-13.95%
Report Date
Nov 14, 2024
EPS Beat/Miss
+4.3%
Price Before
$6.02
Price After
$5.18
Q3 FY2024-7.14%
Report Date
Aug 14, 2024
EPS Beat/Miss
+26.5%
Price Before
$2.66
Price After
$2.47
Avg Beat Reaction-3.84%
Beat Rate8 / 8 quarters
Largest Move-13.95% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: SGMT ends December
Sagimet Biosciences Inc. (SGMT) most recently reported earnings on May 12, 2026 for Q2 FY2026, posting EPS of $-0.33 — beating the analyst consensus of $-0.39 by +15.4%. SGMT has beaten EPS estimates for 9 consecutive quarters. The next SGMT earnings date is expected around September 1, 2026.
Each quarter, investors track SGMT earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. SGMT revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
SGMT's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
SGMT earnings · 5 questionsSagimet Biosciences Inc.'s next earnings report is expected around September 1, 2026. SGMT typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; SGMT historically reports after market close (AMC).
SGMT earnings datewhen is SGMT earningsSGMT next earnings datewhen does SGMT report earningsSGMT earnings calendar
▸ Source: FMP · Sagimet Biosciences Inc. SEC filings · US GAAP · Sagimet Biosciences Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026